We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Next-Gen Heart Failure Management Platform Combines Advanced Interatrial Shunting and Hemodynamic Monitoring

By HospiMedica International staff writers
Posted on 12 Jul 2023

Heart failure, a progressive condition, affects almost 26 million patients around the world. More...

Patients usually complain of impaired functional independence, poor quality of life, and frequent hospitalization associated with heart failure. Now, a next-generation heart failure management platform aims to deliver advanced interatrial shunting and hemodynamic monitoring to overcome the shortcomings of first-generation devices.

Adona Medical’s (Los Gatos, CA, USA) heart failure management platform comprises an adjustable interatrial shunt with integrated bi-atrial pressure monitoring. The shunt flow channel has an adaptable geometry, allowing it to be enlarged or reduced in size at any time post-implantation. This allows for optimizing the shunting flow or dose based on the patient’s needs during the initial procedure, as well as adjustments to be made in the future with the patient’s evolving condition over time. Additionally, the integrated sensors are capable of automatically capturing pressure readings from both the left and right atria several times a day without the need for patient interaction. These daily readings provide physicians with a detailed understanding of the patient’s hemodynamic status and can improve shunt therapy through informed pharmaceutical management.

“Adona Medical is committed to providing heart failure patients and physicians with technologies that address the shortcomings of currently available solutions. You’d struggle to find a physician comfortable with deciding on a fixed dose of medication for a patient and never being able to alter it in the future or monitor its effects, but this is comparable to the use case for interatrial shunts currently under clinical investigation,” said Brian Fahey, Co-Founder and Chief Executive Officer of Adona Medical. “At Adona, we believe that patient care can be pushed forward by a customizable and adjustable shunting approach combined with an advanced hemodynamic monitoring solution.

Related Links:
Adona Medical 


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Blood Bank Refrigerator
MBR-705GR-PE
Cardiograph Device
PageWriter TC35
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.